oxiscurrentreport.htm

0001513160-12-000075.txt : 20121024 0001513160-12-000075.hdr.sgml : 20121024 20121024164421 ACCESSION NUMBER: 0001513160-12-000075 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20121024 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20121024 DATE AS OF CHANGE: 20121024 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OXIS INTERNATIONAL INC CENTRAL INDEX KEY: 0000109657 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 941620407 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-08092 FILM NUMBER: 121159029 BUSINESS ADDRESS: STREET 1: 468 N. CAMDEN DR. STREET 2: 2ND FLOOR CITY: BEVERLY HILLS STATE: CA ZIP: 90210 BUSINESS PHONE: (310) 551-4020 MAIL ADDRESS: STREET 1: 468 N. CAMDEN DR. STREET 2: 2ND FLOOR CITY: BEVERLY HILLS STATE: CA ZIP: 90210 FORMER COMPANY: FORMER CONFORMED NAME: DDI PHARMACEUTICALS INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: DIAGNOSTIC DATA INC /DE/ DATE OF NAME CHANGE: 19850312 8-K 1 oxiscurrentreport.htm OXIS INTERNATIONAL CURRENT REPORT oxiscurrentreport.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 24, 2012

OXIS INTERNATIONAL, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

000-08092		94-1620407
(Commission File Number)		(I.R.S. Employer Identification No.)
468 N. Camden Dr., 2nd Floor Beverly Hills, California		90210
(Address of Principal Executive Offices)		(Zip Code)

	(310) 860-5184
(Registrant’s Telephone Number, Including Area Code)

(Former name, former address, and former fiscal year, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (See General Instruction A.2 below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure

On October 24, 2012, the Company issued a press release announcing its third-quarter revenues. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

Exhibit	Description

99.1	Press Release dated October 24, 2012.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 24, 2012	OXIS INTERNATIONAL, Inc.

	By:	/s/ David Saloff
		David Saloff
		Chief Executive Officer
		(Principal Executive Officer)

EX-99.1 2 ex991.htm PRESS RELEASE DATED OCTOBER 24, 2012 ex991.htm

Exhibit 99.1

OXIS International Announces Significant Revenues During the 3rd Quarter From the Launch of Its Skin Care Product Line

BEVERLY HILLS, Calif., Oct. 24, 2012 (GLOBE NEWSWIRE) -- via PRWEB - OXIS International, Inc., (OXIS) (OXI.PA) today announced revenues for the third quarter were in excess of $110,000. This represents more than a 400% increase in revenues over all of 2011.

David Saloff, OXIS Chairman and CEO stated, "We are extremely pleased with this very successful launch with our partners at Engage BDR. Our initial products, Prograce (http://www.prograceyou.com) and Reverge (http://www.revergeyou.com) are being very well received in the market place. Sales were initiated in July and have been climbing steadily through the quarter with September orders being nearly 300% higher than July's orders. I fully expect that the Company will continue to see significant revenue growth over the next few quarters resulting in a highly profitable 2013 for the Company and its shareholders. More detailed information will be available shortly in the Company's upcoming 10Q filing. We will be keeping the investment community up to date on all exciting developments that take place during the course of the upcoming months."

"The business and science teams at OXIS International have continued to demonstrate tremendous expertise in product development with its EGT product line which we're extremely excited to deliver to the market," said Ted Dhanik, president, engage:BDR.

About OXIS International, Inc.

OXIS International, Inc. develops technologies and products to research, diagnose, treat and prevent diseases of oxidative stress/inflammation associated with damage from free radical and Reactive Oxygen Species (ROS). The company holds the exclusive patent to manufacture EGT, which has received full GRAS (safety) approval. In addition the company holds the rights to several therapeutic classes of compounds in the area of oxidative stress, including EGT(TM) (99% pure L-ergothioneine), known as the intelligent antioxidant.

Contact:

OXIS International

David Saloff

david@oxis.com

424-248-2311